Douglas Bootle
Impact in
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 9
- Cancer therapeutics and mechanisms 3
- Oncology 8
- Cancer Treatment and Pharmacology 5
- Lung Cancer Research Studies 2
- Co-authors
- Alistair Stewart (3 shared papers)Peter Charlton (3 shared papers)Prakash Mistry (3 shared papers)Wendy Dangerfield (3 shared papers)Cornelia Quadt (10 shared papers)Dejan Juric (9 shared papers)Chris Liddle (2 shared papers)Howard A. Burris (6 shared papers)
- Journals
- Cancer Research (4 papers)Journal of Clinical Oncology (3 papers)Anti-Cancer Drugs (2 papers)British Journal of Clinical Pharmacology (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- SwitzerlandUnited StatesSpain
In The Last Decade
Douglas Bootle
17 papers receiving 1.2k citations
Douglas Bootle's Hit Papers
Peers
Comparison fields: 5 of 76
- Oncology 536
- Genetics 128
- Toxicology 35
- Molecular Biology 677
- Cancer Research 124
Countries citing papers authored by Douglas Bootle
This map shows the geographic impact of Douglas Bootle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Bootle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Bootle more than expected).
Fields of papers citing papers by Douglas Bootle
This network shows the impact of papers produced by Douglas Bootle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Bootle. The network helps show where Douglas Bootle may publish in the future.
Co-authors
The 25 scholars most cited alongside Douglas Bootle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Hit paper breakdown → | 2018 | 310 |
| 2 | In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. | 2001 | 309 |
| 3 | 2018 | 192 | |
| 4 | 2009 | 79 | |
| 5 | 2002 | 56 | |
| 6 | 2012 | 51 | |
| 7 | 2013 | 47 | |
| 8 | 2001 | 47 | |
| 9 | BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study | 2012 | 29 |
| 10 | 2014 | 25 | |
| 11 | 2005 | 18 | |
| 12 | 2004 | 17 | |
| 13 | 2015 | 12 | |
| 14 | 2013 | 12 | |
| 15 | 2023 | 10 | |
| 16 | 2014 | 7 | |
| 17 | 2004 | 1 |
About Douglas Bootle
Douglas Bootle is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Genetics and Neurology, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (9 papers), Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (3 papers), Lung Cancer Research Studies (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Pharmacogenetics and Drug Metabolism (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Oncology (536 citations), Genetics (128 citations), Toxicology (35 citations), Molecular Biology (677 citations) and Cancer Research (124 citations). Douglas Bootle has collaborated with scholars based in Switzerland, United States and Spain. Frequent co-authors include Alistair Stewart, Peter Charlton, Prakash Mistry, Wendy Dangerfield, Cornelia Quadt, Dejan Juric, Chris Liddle, Howard A. Burris, Mark R. Middleton and David J. Templeton. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Anti-Cancer Drugs, British Journal of Clinical Pharmacology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.